About Vineet Laboratories Limited
Data last updated:
Vineet Laboratories Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 10 November 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24304TG2016PLC112888. Its GSTIN is 36AAFCV6694P1ZA (Telangana). Its shares are listed on BSE: 543298 and NSE: VINEETLAB.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹19.21 Cr. It is led by directors including Gaddam Venkata Ramana (Managing Director) and Satyanarayana Raju Bhupathiraju (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Hyderabad, Telangana.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹59.4 Cr, a decline of 20.8% compared to the previous year. For the same year it recorded a net profit of ₹1.11 Cr (net margin 1.9%) and EBITDA of ₹8.48 Cr (EBITDA margin 14.3%).
The company has about 69 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Vineet Laboratories. As per MCA filings, the company has open charges of ₹45.08 Cr and satisfied charges of ₹28.34 Cr on record. Court records list 5 cases involving the company, including 4 filed against it. The company has 61 deals on record (61 market trades); the latest was in September 2026. Its 10 peer companies in the Pharma industry (API Manufacturers) are compared by revenue, 5 larger and 5 smaller; the largest is Pratap Organics Private Limited with revenue of ₹78.04 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vineetlabs.co.in.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressSy.No. 11/A3 Saheb Nagar Kurdu Vill Chintal Kunta Eshwaramma Nilayam L B N, Agar, Hyderabad, Telangana, India – 500074
- IndustryPharma, API Manufacturers
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Vineet Laboratories Limited
The main business activity of Vineet Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Vineet Laboratories Limited FY 2025-26 filings available
Vineet Laboratories Limited reported revenue of ₹59.4 Cr (down 20.8% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 59.40 | 75.00 | 151 | 212 | 191 | 243 | 0.00 |
| Revenue growth | -20.8% | -50.2% | -29.1% | +11.1% | -21.5% | - | - |
| EBITDA | 8.48 | (16.28) | 7.20 | 7.65 | 13.15 | 8.14 | (0.01) |
| EBITDA margin | +14.3% | -21.7% | +4.8% | +3.6% | +6.9% | +3.3% | - |
| Profit before tax | 1.28 | (20.77) | 0.36 | 2.02 | 9.33 | 4.05 | (0.01) |
| Net profit | 1.11 | (22.09) | 0.78 | 1.24 | 6.63 | 1.77 | (0.01) |
| Net profit margin | +1.9% | -29.5% | +0.5% | +0.6% | +3.5% | +0.7% | - |
| EPS (₹) | 1.00 | (21.90) | 1.11 | 1.36 | 7.20 | 1.93 | (0.27) |
| Balance sheet | |||||||
| Total assets | - | 55.50 | 79.83 | 65.53 | 61.55 | 40.83 | 0.40 |
| Net worth | - | 14.65 | 34.73 | 33.68 | 33.22 | 26.62 | 0.40 |
| Total debt | - | 40.05 | 44.30 | 31.09 | 26.51 | 12.48 | 0.00 |
| Cash & bank | - | 0.67 | 0.44 | 0.95 | 18.12 | 2.10 | 0.00 |
| Net working capital | - | 29.27 | 52.60 | 39.19 | 32.73 | 20.72 | 0.40 |
| Cash flow | |||||||
| Cash from operations | - | 11.49 | (6.61) | (9.62) | 7.63 | 27.49 | 0.00 |
| Cash from investing | - | (3.18) | (2.22) | (6.69) | (3.68) | (7.81) | 0.00 |
| Cash from financing | - | (8.23) | 8.43 | 0.27 | 11.96 | 18.62 | 0.00 |
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.89 | 15.65 | 17.42 | 7.44 | 14.08 | 18.10 | 18.96 | 23.86 |
| Revenue growth (YoY) | +34.2% | -13.5% | -8.1% | -68.8% | -62.0% | - | - | - |
| Other income | 0.03 | 0.05 | 0.01 | 0.02 | 1.38 | 0.03 | 0.20 | 0.37 |
| Total expenses | 16.40 | 13.16 | 14.24 | 7.12 | 25.12 | 22.24 | 19.26 | 24.66 |
| EBITDA | 2.49 | 2.49 | 3.18 | 0.32 | (11.04) | (4.14) | (0.30) | (0.80) |
| EBITDA margin | +13.2% | +15.9% | +18.3% | +4.3% | -78.4% | -22.9% | -1.6% | -3.4% |
| Depreciation | 0.54 | 0.63 | 0.63 | 0.63 | 0.66 | 0.62 | 0.62 | 0.61 |
| Interest | 0.99 | 1.09 | 2.19 | 0.61 | 0.90 | 0.95 | 0.99 | 1.14 |
| Profit before tax | 0.99 | 0.82 | 0.37 | (0.90) | (11.22) | (5.68) | (1.71) | (2.18) |
| Tax | 0.27 | (0.03) | (0.03) | (0.04) | (0.70) | 0.03 | 0.12 | (0.04) |
Financial Statements
| Particulars | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 18.89 | 15.65 | 17.42 | 7.44 | 14.08 | 18.10 | 18.96 | 23.86 |
| Revenue growth (YoY) | +34.2% | -13.5% | -8.1% | -68.8% | -62.0% | - | - | - |
| Other income | 0.03 | 0.05 | 0.01 | 0.02 | 1.38 | 0.03 | 0.20 | 0.37 |
| Total expenses | 16.40 | 13.16 | 14.24 | 7.12 | 25.12 | 22.24 | 19.26 | 24.66 |
| EBITDA | 2.49 | 2.49 | 3.18 | 0.32 | (11.04) | (4.14) | (0.30) | (0.80) |
| EBITDA margin | +13.2% | +15.9% | +18.3% | +4.3% | -78.4% | -22.9% | -1.6% | -3.4% |
| Depreciation | 0.54 | 0.63 | 0.63 | 0.63 | 0.66 | 0.62 | 0.62 | 0.61 |
| Interest | 0.99 | 1.09 | 2.19 | 0.61 | 0.90 | 0.95 | 0.99 | 1.14 |
| Profit before tax | 0.99 | 0.82 | 0.37 | (0.90) | (11.22) | (5.68) | (1.71) | (2.18) |
| Tax | 0.27 | (0.03) | (0.03) | (0.04) | (0.70) | 0.03 | 0.12 | (0.04) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 59.40 | 75.00 | 151 | 212 | 191 | 243 | 0.00 |
| Revenue growth | -20.8% | -50.2% | -29.1% | +11.1% | -21.5% | - | - |
| Other income | 0.10 | 1.99 | 0.46 | 0.12 | 0.29 | 0.39 | 0.00 |
| Total expenses | 50.92 | 91.28 | 143 | 205 | 178 | 235 | 0.01 |
| Employee cost | 0.00 | 5.34 | 6.38 | 6.00 | 4.91 | 5.57 | 0.00 |
| EBITDA | 8.48 | (16.28) | 7.20 | 7.65 | 13.15 | 8.14 | (0.01) |
| EBITDA margin | +14.3% | -21.7% | +4.8% | +3.6% | +6.9% | +3.3% | - |
| Depreciation | 2.41 | 2.50 | 2.52 | 2.37 | 2.02 | 1.81 | 0.00 |
| Interest | 4.89 | 3.98 | 4.78 | 3.38 | 2.09 | 2.67 | 0.00 |
| Profit before tax | 1.28 | (20.77) | 0.36 | 2.02 | 9.33 | 4.05 | (0.01) |
| Tax | 0.17 | (0.58) | (0.66) | 0.78 | 2.70 | 2.28 | 0.00 |
| Net profit | 1.11 | (22.09) | 0.78 | 1.24 | 6.63 | 1.77 | (0.01) |
| Net profit margin | +1.9% | -29.5% | +0.5% | +0.6% | +3.5% | +0.7% | - |
| EPS (₹) | 1.00 | (21.90) | 1.11 | 1.36 | 7.20 | 1.93 | (0.27) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 9.22 | 9.22 | 9.22 | 9.22 | 9.22 | 0.41 |
| Reserves & surplus | - | 5.43 | 25.51 | 24.46 | 24.00 | 17.40 | (0.01) |
| Shareholders' funds (net worth) | - | 14.65 | 34.73 | 33.68 | 33.22 | 26.62 | 0.40 |
| Secured loans | - | 3.08 | 3.53 | 4.59 | 1.46 | 3.47 | 0.00 |
| Unsecured loans | - | 36.97 | 40.77 | 26.50 | 25.05 | 9.01 | 0.00 |
| Total debt | - | 40.05 | 44.30 | 31.09 | 26.51 | 12.48 | 0.00 |
| Total liabilities | - | 55.50 | 79.83 | 65.53 | 61.55 | 40.83 | 0.40 |
| Assets | |||||||
| Gross block | - | 50.69 | 49.64 | 46.85 | 39.22 | 35.48 | 0.00 |
| Net block | - | 25.46 | 26.91 | 26.64 | 21.39 | 19.66 | 0.00 |
| Capital work in progress | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | - | 0.21 | 0.18 | 0.13 | 0.14 | 0.12 | 0.00 |
| Inventories | - | 49.97 | 49.39 | 46.17 | 43.54 | 39.69 | 0.00 |
| Sundry debtors | - | 13.25 | 31.60 | 35.16 | 36.20 | 42.71 | 0.00 |
| Cash & bank balances | - | 0.67 | 0.44 | 0.95 | 18.12 | 2.10 | 0.00 |
| Loans & advances | - | 3.51 | 6.75 | 5.18 | 4.85 | 1.86 | 0.40 |
| Total current assets | - | 67.40 | 88.18 | 87.46 | 103 | 86.36 | 0.40 |
| Total current liabilities | - | 38.13 | 35.58 | 48.27 | 69.98 | 65.64 | 0.00 |
| Net working capital | - | 29.27 | 52.60 | 39.19 | 32.73 | 20.72 | 0.40 |
| Total assets | - | 55.50 | 79.83 | 65.53 | 61.55 | 40.83 | 0.40 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.23 | 0.63 | 16.66 | 0.75 | 0.00 | 0.01 |
| Net cash from operating activities | - | 11.49 | (6.61) | (9.62) | 7.63 | 27.49 | 0.00 |
| Net cash from investing activities | - | (3.18) | (2.22) | (6.69) | (3.68) | (7.81) | 0.00 |
| Net cash from financing activities | - | (8.23) | 8.43 | 0.27 | 11.96 | 18.62 | 0.00 |
| Net change in cash | - | 0.08 | (0.40) | (16.03) | 15.91 | 38.30 | 0.00 |
| Closing cash | - | 0.67 | 0.44 | 0.95 | 18.12 | 2.10 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -20.8% | -50.2% | -29.1% | +11.1% | -21.5% | - | - |
| EBITDA growth | +152.1% | -326.1% | -5.9% | -41.8% | +61.6% | - | - |
| PBT growth | +9998.0% | - | -82.2% | -78.4% | +130.4% | +9998.0% | +9997.0% |
| Net income growth | +105.0% | -2932.1% | -37.1% | -81.3% | +274.6% | - | - |
| Revenue CAGR (3Y) | -34.6% | -26.8% | -14.8% | - | - | - | - |
| EBITDA CAGR (3Y) | +3.5% | - | -4.0% | - | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +1.9% | -26.9% | +0.7% | +0.6% | +3.5% | +0.7% | - |
| Return on capital employed | - | 0.0% | +6.6% | +8.5% | +22.4% | +32.6% | 0.0% |
| Return on net worth | - | 0.0% | +2.3% | +3.7% | +22.2% | +13.2% | 0.0% |
| Debt / equity | - | 1.71 | 1.10 | 0.86 | 0.65 | 0.46 | 0.00 |
| Long-term debt / equity | - | 0.16 | 0.13 | 0.10 | 0.09 | 0.13 | 0.00 |
| Interest cover | 80.56 | -21.19 | 102.14 | 64.02 | 18.78 | 42.18 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 1.50 | 3.12 | 4.93 | 5.12 | 13.72 | 0.00 |
| Inventory turnover | - | 1.51 | 3.15 | 4.73 | 4.59 | 12.27 | 0.00 |
| Debtors turnover | - | 3.34 | 4.51 | 5.95 | 4.85 | 11.40 | 0.00 |
| EPS (₹) | 1.00 | (21.90) | 1.11 | 1.36 | 7.20 | 1.93 | (0.27) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 15.89 | 37.67 | 36.54 | 36.03 | 28.87 | 9.73 |
Peer Comparison of Vineet Laboratories Limited
Vineet Laboratories Limited is compared with the companies closest to it by revenue in the Pharma industry (API Manufacturers). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Pratap Organics Private Limited | ₹78.04 Cr (FY 2024) | •••• | •••• | 0.0% | •••• | Navi Mumbai, Maharashtra, India |
| V-Ensure Pharma Technologies Private Limited | ₹77.73 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Navi Mumbai, Maharashtra, India |
| Asence Pharma Private Limited | ₹77.56 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | Vadodara, Gujarat, India |
| J P N Pharma Private Limited | ₹77.5 Cr (FY 2024) | •••• | •••• | 0.0% | •••• | Mumbai, Maharashtra, India |
| Vimal Drugs Private Limited | ₹76.99 Cr (FY 2025) | •••• | •••• | 55.0% | •••• | Hyderabad, Telangana, India |
| Pentagon Labs Limited | ₹76.72 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Indore, Madhya Pradesh, India |
| Innovare Labs Private Limited | ₹76.64 Cr (FY 2024) | •••• | •••• | -8.0% | •••• | Hyderabad, Telangana, India |
| Harika Drugs Private Limited | ₹76.53 Cr (FY 2024) | •••• | •••• | 6.0% | •••• | Hyderabad, Telangana, India |
| Andhra Medi Pharma India Private Limited | ₹76.02 Cr (FY 2025) | •••• | •••• | 26.0% | •••• | Vijayawada, Andhra Pradesh, India |
| Aalidhra Pharmachem Private Limited | ₹74.98 Cr (FY 2024) | •••• | •••• | -16.0% | •••• | Surat, Gujarat, India |
| Vineet Laboratories Limited this company | ₹59.4 Cr (FY 2026) | •••• | •••• | -20.8% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Vineet Laboratories by revenue in the Pharma industry (API Manufacturers), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Vineet Laboratories Limited
Vineet Laboratories Limited is audited by NSVR & Associates LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| NSVR & Associates LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Vineet Laboratories Limited
Vineet Laboratories has 7 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gaddam Venkata Ramana Also directs: Vineet Chem Trade Private Limited, Wohler Laboratories Private Limited, Vineet Life Sciences Limited and 1 more | Managing Director | 10 Nov 2016 | 9 Years 10 Months | Current |
| Satyanarayana Raju Bhupathiraju Also directs: Vineet Life Sciences Limited | Whole-Time Director | 10 Nov 2016 | 9 Years 10 Months | Current |
| Dilip Vishnu Acharekar | Director | 16 Nov 2020 | 5 Years 10 Months | Current |
| Ranga Raju Alluri | Director | 12 Aug 2023 | 3 Years 1 Months | Current |
| Jasmin Kunal Tailor Also directs: Stylesphere Collective Private Limited | Director | 09 Nov 2025 | 0 Years 11 Months | Current |
| Premananda Reddy Vennapusa | Director | 15 Sep 2025 | 1 Years 0 Months | Current |
Shareholding Pattern of Vineet Laboratories Limited
Shareholding for the quarter ended Sep 2026: promoters hold 6.00%, foreign institutional investors hold 0.50%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 93.50%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 6.00% | 6.00% | 12.50% | 15.90% |
| Public | 94.00% | 94.00% | 87.50% | 84.10% |
Charges & Borrowings of Vineet Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 May 2022 | Hdfc Bank Limited | ₹44.9 Cr | Open |
| 01 Jan 2022 | Hdfc Bank Limited | ₹17.78 Lakh | Open |
| 25 Mar 2022 | Karnataka Bank Ltd. | ₹21.56 Lakh | Satisfied |
| 24 Mar 2022 | Karnataka Bank Ltd. | ₹28.12 Cr | Satisfied |
Total charge records: 4 View all charges
Deals & Funding of Vineet Laboratories Limited
Vineet Laboratories Limited has 61 deals on record (61 market trades); the latest was in September 2026.
Deals on record (5 of 61)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Market trade | ₹1.77 Cr | Buyer: Galaxy Prime Private Limited Seller: 3 individuals |
| Feb 2026 | Market trade | ₹16.5 Lakh | Seller: Multiplier Share and Stock Advisors Private Limited |
| Jan 2026 | Market trade | ₹73.9 Lakh | Buyer: HJS Securities Private Limited , 3 individuals Seller: HJS Securities Private Limited , an individual |
| Oct 2025 | Market trade | ₹23.5 Lakh | Buyer: HJS Securities Private Limited Seller: HJS Securities Private Limited |
| Oct 2025 | Market trade | ₹92.5 Lakh | Buyer: Amit Kumar Jain Huf, Irage Broking Services LLP , Hensex Securities Private Limited , an individual Seller: Amit Kumar Jain Huf, Irage Broking Services LLP , Hensex Securities Private Limited |
Full deal history
All 61 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Vineet Laboratories Limited
Vineet Laboratories Limited has 5 court cases on record: 4 filed against it, 1 where it is another party. All cases are disposed. Status as checked between 30 Sep 2026 and 03 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 5 | 4 | 0 |
Cases on record (3 of 5)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by an individual | Disposed |
| District court, Vadodara, Gujarat | Court case (CR EN) | Filed against the company by an individual | Disposed |
| District court, Nalgonda, Telangana | Court case (MVOP) | Company is another party | Disposed |
Full case history
All 5 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Associated Brands with Vineet Laboratories Limited
Vineet Laboratories operates one associated brand: Vineet Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| APIs are manufactured by Vineet Laboratories as a CDMO. | vineetlabs.co.in |
Employees and EPFO Compliance at Vineet Laboratories Limited
Vineet Laboratories Limited has a workforce of 69 employees as of Apr 03, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Vineet Laboratories Limited
Vineet Laboratories has one previous CIN (Corporate Identification Number): U24304TG2016PLC112888. The current CIN is L24304TG2016PLC112888, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24304TG2016PLC112888 | Current |
| U24304TG2016PLC112888 | Previous |
News related to Vineet Laboratories Limited
Recent Activity on Vineet Laboratories Limited
Vineet Laboratories Limited has 19 board changes on record since 2016: 13 appointments and 6 cessations. The latest: Rajesh Kumar Kathulla was appointed as Additional Director on 11 Jun 2026.
17 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Vineet Laboratories Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Vineet Laboratories Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Vineet Laboratories Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Vineet Laboratories Limited
Vineet Laboratories has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCV6694P1ZA | Telangana | Active | 11 Nov 2020 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Vineet Laboratories Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vineet Laboratories Limited
Vineet Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 10 November 2016 (10+ years old) and is registered under CIN L24304TG2016PLC112888. Listed on BSE: 543298 and NSE: VINEETLAB.
Vineet Laboratories reported revenue of ₹59.4 Cr for FY 2025-26 (down 20.8% YoY) based on standalone financials.
Vineet Laboratories has 7 current directors:
- Gaddam Venkata Ramana - Managing Director
- Satyanarayana Raju Bhupathiraju - Whole-Time Director
- Dilip Vishnu Acharekar - Director
- Ranga Raju Alluri - Director
- Jasmin Kunal Tailor - Director
- Premananda Reddy Vennapusa - Director
- Rajesh Kumar Kathulla - Additional Director
The GSTIN of Vineet Laboratories is 36AAFCV6694P1ZA, registered in Telangana.
The CIN (Corporate Identification Number) of Vineet Laboratories is L24304TG2016PLC112888. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Vineet Laboratories is listed on both BSE (code: 543298) and NSE (symbol: VINEETLAB).
Vineet Laboratories has 5 court cases on record: 4 filed against it.
Vineet Laboratories was incorporated on 10 November 2016, making it 10+ years old. It is registered with the Registrar of Companies, Hyderabad.
Vineet Laboratories has 61 deals on record (61 market trades); the latest was in September 2026.
The peers of Vineet Laboratories by revenue are Pratap Organics Private Limited, V-Ensure Pharma Technologies Private Limited, Asence Pharma Private Limited, J P N Pharma Private Limited, Vimal Drugs Private Limited and 5 more, all in the Pharma industry (API Manufacturers).
Rajesh Kumar Kathulla was appointed as Additional Director on 11 Jun 2026. Hari Priya Yerukalapudi ceased to be Director on 09 Nov 2025. Jasmin Kunal Tailor was appointed as Director on 09 Nov 2025. Vineet Laboratories has 19 board changes on record in total.